| Translational/basic science |
What are the hallmarks of early SpA and pre-SpA? Better understanding of the links between intestinal disease and the pathogenesis of SpA Improve international collaborations to set up registries and bio-banks on SpA in order to share experience and resources for research
|
|
| Clinical science/therapeutic trials |
Improve our knowledge of peripheral SpA, particularly the disease course and the response to therapy. This can be addressed by large cohort studies Design strategy trials to study the optimal use and choice of biologics and small molecules that will deliver the best outcome in SpA Head-to-head trials that compare the efficacy of different biologics in SpA Can early treatment modify the disease course
|
Understanding the biological basis of non-responders to current therapies, especially biologics Identify biomarkers and imaging and clinical markers that differentiate subsets of SpA that respond preferentially to one or another therapy Better understand the effects of treatment of SpA on inflammation of the eye and the gut International collaboration to conduct strategy trials Conduct T2T trials with clinical remission as the target
|
| Clinical care |
|
|